Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 19/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 19/20 | 1.00 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426444 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BELANE | |
| SCHEMBL2294565 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BELANE | |
| SCHEMBL29538473 | 0.91 | MTNR1A (0.83) | MTNR1AMTNR1B | |
| SCHEMBL2301204 | 0.91 | MTNR1A (0.83) | MTNR1AMTNR1B | |
| SCHEMBL2301201 | 0.91 | MTNR1A (0.83) | MTNR1AMTNR1B | |
| SCHEMBL11931986 | 0.82 | MTNR1A (0.69) | MTNR1AMTNR1B | |
| SCHEMBL2296488 | 0.82 | MTNR1A (0.69) | MTNR1AMTNR1B | |
| SCHEMBL2296484 | 0.82 | MTNR1A (0.69) | MTNR1AMTNR1B | |
| SCHEMBL2299352 | 0.80 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL2299350 | 0.80 | MTNR1A (1.00) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3400940-B1 | COMPOUNDS HAVING MELATONIN RECEPTOR AFFINITY AS PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | TAKEDA PHARMACEUTICALS CO (JP) | 2024-08-07 | — | — | EP | claimed |
| US-20220096444-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-31 | — | — | US | claimed |
| EP-3400939-B1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-16 | — | — | EP | claimed |
| US-20210130305-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2021-05-06 | — | — | US | claimed |
| US-10759768-B2 | Prophylactic or therapeutic agent for autism spectrum disorder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-01 | — | — | US | claimed |
| US-20190040022-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-07 | — | — | US | claimed |
| US-20190008834-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-10 | — | — | US | claimed |
| EP-3400939-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | Takeda Pharmaceutical Company Limited (JP) | 2018-11-14 | — | — | EP | claimed |
| EP-3400940-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | Takeda Pharmaceutical Company Limited (JP) | 2018-11-14 | — | — | EP | claimed |
| EP-2029561-B1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | claimed |
| US-8552037-B2 | Tricyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-08 | — | — | US | claimed |
| US-20130079374-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-28 | — | — | US | claimed |
| US-20090182023-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-16 | — | — | US | claimed |
| EP-3400940-B1 | COMPOUNDS HAVING MELATONIN RECEPTOR AFFINITY AS PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | TAKEDA PHARMACEUTICALS CO (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-108697689-B | Prophylactic or therapeutic agent for autism spectrum disorder | 武田药品工业株式会社 | 2022-04-26 | — | — | CN | disclosed |
| US-20220096444-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-31 | — | — | US | disclosed |
| US-20090182023-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182023-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182023-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| WO-2007148808-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190008834-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | MTNR1A, MTNR1B, PNMT | MTNR1A 1/4885MTNR1B 2/4885ELANE 4009/4885 |
| US-20190040022-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | MTNR1A, MTNR1B, MCHR1 | MTNR1A 1/4885MTNR1B 2/4885ELANE 3706/4885 |
| US-20220096444-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DELIRIUM | MTNR1A, MTNR1B, PNMT | MTNR1A 1/4885MTNR1B 2/4885ELANE 4009/4885 |
| US-20090182023-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, CYP11B2 | MTNR1A 1/4885MTNR1B 2/4885ELANE 1689/4885 |
| US-20210130305-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AUTISM SPECTRUM DISORDER | MTNR1A, MTNR1B, MCHR1 | MTNR1A 1/4885MTNR1B 2/4885ELANE 3706/4885 |
| US-10759768-B2 | Prophylactic or therapeutic agent for autism spectrum disorder | MTNR1A, MTNR1B, MCHR1 | MTNR1A 1/4885MTNR1B 2/4885ELANE 3706/4885 |
| US-20130079374-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, CYP11B2 | MTNR1A 1/4885MTNR1B 2/4885ELANE 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.